Stock Analiz

Nektar Therapeutics (NKTR) stock forecast and price target

Price $37.27 · data as of November 13, 2026

12-month price target

Average target$131.92
Upside / downside+253.9%
Analysts12
ConsensusBuy
Low $40.00Average $131.92High $192.00

Gold marker: average target · white marker: today’s price ($37.27)

Analyst ratings

Strong buy 1Buy 10Hold 4Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-7.21+17.0%$41M
Next fiscal year
ends December 31, 2027
$-9.80−38.1%$51M
Next quarter
ends December 31, 2026
$-2.41−90.7%$9M
Quarter after
ends March 31, 2027
$-2.51−38.2%$9M

Consensus of the analysts covering Nektar Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 0 lowered.

Frequently asked questions

What is the Nektar Therapeutics stock price target?

The average 12-month target from 12 analysts is $131.92, 253.9% above the current price of $37.27 Targets range from $40.00 to $192.00.

Is Nektar Therapeutics a buy according to analysts?

The consensus rating is “Buy” (1 strong buy, 10 buy, 4 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Nektar Therapeutics expected to earn?

Analysts expect EPS of $-7.21 for the fiscal year ending December 31, 2026 and $-9.80 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.